Genpharmasec Limited has informed BSE Limited of an upcoming Board of Directors meeting scheduled for Thursday, May 21, 2026, at the company's registered office. The intimation, dated May 13, 2026, was filed in accordance with Regulation 29 read with Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Board Meeting Agenda

The Board of Directors will convene to deliberate on key financial matters. The following items have been listed on the agenda for the meeting:

In addition to the primary agenda, the board will also consider any other business with the permission of the Chairman of the Meeting.

Trading Window Closure

In line with the provisions of SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's own Code of Conduct for Prevention of Insider Trading, Genpharmasec has implemented a trading window closure. The key details of this restriction are as follows:

• Applicable Persons: All Directors, Designated Persons, their immediate relatives, and specified Connected Persons
• Closure Start Date: Wednesday, April 1, 2026
• Closure End Date: 48 hours after the declaration of audited financial results for the quarter and year ended March 31, 2026
• Securities Covered: Securities of Genpharmasec Limited

The trading window closure remains in effect on both the start and end dates inclusive.

Signatory Details

The board meeting intimation was submitted to BSE Limited's Compliance Department of Corporate Services at Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400 001, and was digitally signed by Mr. Sohan Chaturvedi, Whole Time Director and CFO (DIN: 09629728), on May 13, 2026, at 11:10:04 IST.

Genpharmasec Limited has formally declared to BSE Limited that it does not fall under the Large Corporate (LC) framework as specified in SEBI regulations. The declaration was made on April 14, 2026, providing clarity on the company's regulatory compliance status.

SEBI Circular Compliance Declaration

The company's declaration specifically references two key SEBI circulars that govern Large Corporate regulations:

These circulars establish the framework for fund raising through debt securities issuance by entities classified as Large Corporates and mandate specific disclosure requirements for such companies.

Company's Regulatory Status

Genpharmasec Limited has clearly stated that it does not meet the criteria to be classified as a Large Corporate under the SEBI framework. This determination has significant implications for the company's regulatory obligations and compliance requirements.

The declaration was signed by Mr. Sohan Chaturvedi, Whole Time Director and CFO (DIN: 09629728), and submitted to BSE Limited's Compliance Department of Corporate Services. The company operates from its registered office at 104 & 105, 1st Floor, Gundecha Industrial Premises Co-Operative Society Limited, Akurli Road, Kandivali (East), Mumbai 400101.

Compliance Implications

By confirming its non-Large Corporate status, Genpharmasec Limited is exempt from the disclosure obligations typically required under the referenced SEBI circulars. This exemption relieves the company from filing specific disclosures related to debt securities issuance frameworks applicable to Large Corporates.

The formal declaration ensures transparency with regulatory authorities and provides stakeholders with clear information about the company's compliance status under current SEBI regulations governing corporate debt fundraising activities.